Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
BackgroundBevacizumab is the representative drug in antiangiogenic therapy for lung cancer. However, it induced resistance in some neoplasm. Anlotinib, a novel multi-target tyrosine kinase inhibitor which has an inhibitory action on both angiogenesis and malignancy, is possible to reverse the resist...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2022-05-01
|
| Collection: | Frontiers in Oncology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fonc.2022.875888/full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|